Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This trial will determine the pharmacokinetics of Posiphen® in both plasma and CSF after a
10-day treatment period with Posiphen® in subjects with amnestic MCI. The effects of this
treatment on biomarkers will also be determined in CSF, whole blood, and plasma or serum as
primary pharmacodynamic (PD) objectives.